Rating Rationale
August 30, 2018 | Mumbai
Relisys Medical Devices Limited
Rating Reaffirmed 
 
Rating Action
Rs.31 Crore Non Convertible Debentures CRISIL B-/Stable (Reaffirmed)
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has reaffirmed its rating on the non-convertible debentures (NCDs) of Relisys Medical Devices Ltd (RMD) at 'CRISIL B-/Stable'.
 
The rating reflects a small scale of operations, large working capital requirement, exposure to high refinancing risk, and constrained financial flexibility on account of large bullet payment. The rating also factors in a below-average financial risk profile, constrained by planned investment in another entity and modest debt protection metrics. These weaknesses are partially offset by the extensive experience of the promoters in the medical devices manufacturing industry and a healthy operating margin.

Key Rating Drivers & Detailed Description
Weakness
* Small scale of operations
Revenue was modest at Rs 42.2 crore in fiscal 2018. Moreover, working capital requirement is large, as indicated by gross current assets, inventory, and debtors of 313, 138, and 229 days, respectively, as on March 31, 2018. 
 
* Exposure to high refinancing risk
The principal along with the accumulated interest on the NCDs (about Rs 82 crore) is to be repaid as a bullet payment in October 2019. This constrains the financial flexibility and also exposes the company to high risk related to timely refinancing of debt.
 
* Below-average financial risk profile
Equity infusion of about Rs 29 crore in fiscal 2018 led to an increase in the networth to Rs 27.2 crore as on March 31, 2018, from a negative Rs 5.64 crore earlier. However, most of the funds infused will be utilised for acquisition of another company. The interest coverage ratio was also modest at 1.78 times in fiscal 2018.
 
Strengths
* Extensive industry experience of the promoters
RMD was established in 1997, promoted by a group of doctors, including, Dr. N.Krishna Reddy, Dr. B K S Sastry, and Dr. N Ramakrishna Rao. Dr. Krishna Reddy has extensive experience in the healthcare and medical devices manufacturing industry. Also Mr. Subramanian Sivaraman, who is having over 24 years' experience in new product development, production and finance in medical devices and other industries has joined the business. He was a promoter and also ex- Managing Director of a medical consumables manufacturing and marketing company, with worldwide sales and had been instrumental in the company's vertical integration in key product areas as well as building the company into the second largest player in the sutures market in India. Benefits from the extensive industry experience of the promoters are expected to continue over the medium term.
 
* Healthy operating margin
The margin was volatile because of a change in the revenue mix and remains susceptible to fluctuation in raw material prices and to government regulation on prices of stent systems. However, the margin remained healthy at 24.5-49.1% in the three fiscals through 2018.
Outlook: Stable

CRISIL believes the business risk profile will continue to be supported by the extensive industry experience of the promoters. The outlook may be revised to 'Positive' if significant equity infusion, along with timely refinancing of debt at a lower rate of interest, results in improvement in key credit metrics. The outlook may be revised to 'Negative' in case of lower-than-expected net cash accrual, or a significant stretch in receivables, leading to deterioration in the financial risk profile.

About the Company

Set up in 1998, RMD designs, develops, and manufactures critical care devices such as stents, catheters, and stent systems used to treat cardiovascular, peripheral vascular, neurovascular (stroke), and other life-threatening diseases. Operations are managed by Dr N Krishna Reddy (Chairman & Managing Director) , and Mr. Subramanian Sivaraman (Director-Operations). Mr. Subramanian is an ex-Managing Director of reputed Medical Devices Company, and is having rich experience in finance, manufacturing and operations.

Key Financial Indicators
Particulars Unit 2018 2017
Revenue Rs crore 42.17 25.9
Profit after tax (PAT) Rs crore 5.9 11.75
PAT margin % 14.0 45.4
Adjusted debt/Adjusted networth Times 1.28 (6.69)
Interest coverage Times 1.78 27.21

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of the instrument Date of issuance Coupon Rate (%) Maturity Date Issue Size
(Rs. Cr)
Rating Assigned
with Outlook
INE959H07011 Non-Convertible Debentures 22-Oct-14 22% 22-Oct-19 25 CRISIL B-/Stable
INE959H07029 Non-Convertible Debentures 30-Oct-15 22% 30-Oct-19 6 CRISIL B-/Stable
 
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Non Convertible Debentures  LT  31.00
28-08-18 
CRISIL B-/Stable      10-08-17  CRISIL B-/Stable  20-06-16  CRISIL B-/Stable  05-10-15  CRISIL B-/Stable  CRISIL B-/Stable 
                    21-05-15  CRISIL B-/Stable   
Fund-based Bank Facilities  LT/ST    --    --    --  20-06-16  Withdrawal  05-10-15  CRISIL B-/Stable  CRISIL B-/Stable 
                    21-05-15  CRISIL B-/Stable   
Non Fund-based Bank Facilities  LT/ST    --    --    --    --    --  CRISIL A4 
All amounts are in Rs.Cr.
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Rahul Guha
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Nagarjun Alaparthi
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 40 4032 8210
Nagarjun.Alaparthi@crisil.com


Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL